AGN-151586 + BOTOX + Placebo
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glabellar Lines
Conditions
Glabellar Lines
Trial Timeline
Aug 30, 2022 → May 30, 2023
NCT ID
NCT05496335About AGN-151586 + BOTOX + Placebo
AGN-151586 + BOTOX + Placebo is a phase 1 stage product being developed by AbbVie for Glabellar Lines. The current trial status is completed. This product is registered under clinical trial identifier NCT05496335. Target conditions include Glabellar Lines.
What happened to similar drugs?
0 of 11 similar drugs in Glabellar Lines were approved
Approved (0) Terminated (0) Active (11)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05496335 | Phase 1 | Completed |
Competing Products
19 competing products in Glabellar Lines
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + AGN-151586 | AbbVie | Phase 3 | 40 |
| AGN-151586 + Placebo | AbbVie | Phase 3 | 40 |
| AGN-151586 + OnabotulinumtoxinA + Placebo | AbbVie | Phase 1 | 29 |
| AGN-151586 + Placebo | AbbVie | Phase 3 | 40 |
| AGN-151586 | AbbVie | Phase 3 | 40 |
| AGN-151586 + Placebo | AbbVie | Phase 1 | 29 |
| Botulinum toxin type A + Botulinum toxin type A + Placebo + Placebo | Ipsen | Phase 3 | 37 |
| IPN10200 + Placebo | Ipsen | Phase 3 | 44 |
| Botulinum toxin type A + Placebo | Ipsen | Phase 3 | 37 |
| Botulinum toxin type A + Botulinum toxin type A + Placebo | Ipsen | Phase 2 | 32 |
| Botulinum toxin type A + Placebo | Ipsen | Phase 3 | 37 |
| IPN10200 + Placebo | Ipsen | Phase 3 | 44 |
| prabotulinumtoxinA | Evolus | Pre-clinical | 20 |
| PrabotulinumtoxinA-Xvfs + OnabotulinumtoxinA + PrabotulinumtoxinA-Xvfs | Evolus | Phase 2 | 25 |
| Botulinum toxin, Type A | Evolus | Phase 3 | 30 |
| DWP-450 (Botulinum purified neurotoxin, Type A) | Evolus | Phase 2 | 25 |
| Botulinum toxin, Type A | Evolus | Phase 3 | 30 |
| Botulinum purified neurotoxin, Type A | Evolus | Phase 2 | 25 |
| prabotulinumtoxinA | Evolus | Phase 1 | 19 |